IGHE and asthma: The identification of the inflammatory endotype and the prediction of a specific treatment response rely on validated non-invasive biomarkers, such as eosinophils (in blood and sputum), IgE, fractional exhaled nitric oxide (FeNO), and serum periostin, which are available in clinical practice and are related to T2 asthma endotype (7, 17–19).